ExpreS2ion Biotech Holding AB (EXPRS2) - Total Liabilities

Latest as of March 2026: Skr23.98 Million SEK ≈ $2.58 Million USD

Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has total liabilities worth Skr23.98 Million SEK (≈ $2.58 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ExpreS2ion Biotech Holding AB - Total Liabilities Trend (2013–2025)

This chart illustrates how ExpreS2ion Biotech Holding AB's total liabilities have evolved over time, based on quarterly financial data. See EXPRS2 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

ExpreS2ion Biotech Holding AB Competitors by Total Liabilities

The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their total liabilities.

Company	Country	Total Liabilities
CFI-Compagnie FonciÃ¨re Internationale PA:CFI	France	€225.00K
Prosper Gold Corp. V:PGX	Canada	CA$200.32K
Fitness Champs Holdings Limited Common Stock NASDAQ:FCHL	USA	$1.90 Million
BioSenic S.A. BR:BIOS	Belgium	€28.10 Million
Shirpur Gold Refinery Limited NSE:SHIRPUR-G	India	Rs7.39 Billion
Oncternal Therapeutics Inc NASDAQ:ONCT	USA	$6.45 Million
Golden Cross Resources Ltd AU:GCR	Australia	AU$10.33 Million
BlackRock Latin American Investment Trust plc LSE:BRLA	UK	GBX824.00K

Liability Composition Analysis (2013–2025)

This chart breaks down ExpreS2ion Biotech Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ExpreS2ion Biotech Holding AB market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.91	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ExpreS2ion Biotech Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ExpreS2ion Biotech Holding AB (2013–2025)

The table below shows the annual total liabilities of ExpreS2ion Biotech Holding AB from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr29.42 Million ≈ $3.17 Million	-26.65%
2024-12-31	Skr40.11 Million ≈ $4.32 Million	+200.95%
2023-12-31	Skr13.33 Million ≈ $1.43 Million	-60.84%
2022-12-31	Skr34.04 Million ≈ $3.66 Million	+193.16%
2021-12-31	Skr11.61 Million ≈ $1.25 Million	-52.24%
2020-12-31	Skr24.31 Million ≈ $2.62 Million	+22.86%
2019-12-31	Skr19.79 Million ≈ $2.13 Million	+56.37%
2018-12-31	Skr12.65 Million ≈ $1.36 Million	+20.53%
2017-12-31	Skr10.50 Million ≈ $1.13 Million	-10.54%
2016-12-31	Skr11.73 Million ≈ $1.26 Million	+16.19%
2015-12-31	Skr10.10 Million ≈ $1.09 Million	+222.22%
2014-12-31	Skr3.13 Million ≈ $337.34K	+44.07%
2013-12-31	Skr2.18 Million ≈ $234.15K	--

About ExpreS2ion Biotech Holding AB

ST:EXPRS2 Sweden Biotechnology

Market Cap

$1.56 Million

Skr14.53 Million SEK

Market Cap Rank

#30177 Global

#708 in Sweden

Share Price

Skr1.47

Change (1 day)

-5.16%

52-Week Range

Skr1.47 - Skr28.05

All Time High

Skr1818.80